|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-7-19
|
|
pubmed:abstractText |
The benefits of high-dose cytarabine, anthracyclines and hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia (AML) are greater in younger rather than in older patients. We assessed the proportion of patients over 60 years with de novo AML who qualified for intensive therapy and determined the feasibility and results of autologous stem cell transplantation (ASCT) in first complete remission (CR).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
pubmed-author:BatlleMontserratM,
pubmed-author:BesalduchJoanJ,
pubmed-author:BrunetSalutS,
pubmed-author:BuenoJavierJ,
pubmed-author:CETLAM AML-99,
pubmed-author:CarrerasEnricE,
pubmed-author:EsteveJordiJ,
pubmed-author:FeliuEvaristE,
pubmed-author:GuàrdiaRamonR,
pubmed-author:HamraouiKarimK,
pubmed-author:JuliàAntoniA,
pubmed-author:LlorenteAndrésA,
pubmed-author:MontserratEmiliE,
pubmed-author:OriolAlbertA,
pubmed-author:RiberaJosep-MariaJM,
pubmed-author:SánchezJosep-MariaJM,
pubmed-author:SierraJordiJ,
pubmed-author:TormoMarM,
pubmed-author:VilàJosep-MariaJM,
pubmed-author:VivancosPilarP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
791-800
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15257930-Acute Disease,
pubmed-meshheading:15257930-Age Factors,
pubmed-meshheading:15257930-Aged,
pubmed-meshheading:15257930-Aged, 80 and over,
pubmed-meshheading:15257930-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15257930-Combined Modality Therapy,
pubmed-meshheading:15257930-Cytarabine,
pubmed-meshheading:15257930-Disease-Free Survival,
pubmed-meshheading:15257930-Etoposide,
pubmed-meshheading:15257930-Female,
pubmed-meshheading:15257930-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:15257930-Humans,
pubmed-meshheading:15257930-Idarubicin,
pubmed-meshheading:15257930-Leukemia, Myeloid,
pubmed-meshheading:15257930-Logistic Models,
pubmed-meshheading:15257930-Male,
pubmed-meshheading:15257930-Middle Aged,
pubmed-meshheading:15257930-Mitoxantrone,
pubmed-meshheading:15257930-Proportional Hazards Models,
pubmed-meshheading:15257930-Remission Induction,
pubmed-meshheading:15257930-Transplantation, Autologous
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
|
|
pubmed:affiliation |
CETLAM Group, Catalonia, Spain. aoriol@ns.hugtip.scs.es
|
|
pubmed:publicationType |
Journal Article,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
